Cidel Asset Management Inc. Sells 1,593 Shares of Eli Lilly and Company $LLY

Cidel Asset Management Inc. cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,133 shares of the company’s stock after selling 1,593 shares during the period. Eli Lilly and Company makes up about 1.9% of Cidel Asset Management Inc.’s portfolio, making the stock its 14th biggest holding. Cidel Asset Management Inc.’s holdings in Eli Lilly and Company were worth $27,010,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Leo Wealth LLC lifted its stake in shares of Eli Lilly and Company by 54.8% in the 4th quarter. Leo Wealth LLC now owns 3,107 shares of the company’s stock valued at $3,340,000 after purchasing an additional 1,100 shares during the last quarter. MBA Advisors LLC lifted its stake in shares of Eli Lilly and Company by 6.2% in the 4th quarter. MBA Advisors LLC now owns 568 shares of the company’s stock valued at $610,000 after purchasing an additional 33 shares during the last quarter. Elwood & Goetz Wealth Advisory Group LLC lifted its stake in shares of Eli Lilly and Company by 12.6% in the 4th quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 437 shares of the company’s stock valued at $470,000 after purchasing an additional 49 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its stake in shares of Eli Lilly and Company by 8.3% in the 4th quarter. Walkner Condon Financial Advisors LLC now owns 1,451 shares of the company’s stock valued at $1,559,000 after purchasing an additional 111 shares during the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC lifted its stake in shares of Eli Lilly and Company by 12.4% in the 4th quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 5,755 shares of the company’s stock valued at $6,185,000 after purchasing an additional 633 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial setup: Lilly secured approval for its oral weight‑loss drug Foundayo and management says production is ready to scale, supporting near‑term revenue upside from obesity treatments. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: Buy arguments and analyst support: multiple bullish writeups (including a “3 Reasons To Buy” piece and a modest price‑target raise after approval) highlight durable cash flows from GLP‑1 drugs and refreshed upside assumptions. 3 Reasons To Buy Eli Lilly Now Price Target Raised After FDA Approval
• Positive Sentiment: Pipeline diversification: Lilly amended its collaboration with AC Immune to advance next‑generation tau inhibitors toward IND‑enabling studies in 2026, expanding long‑term Alzheimer’s/neurodegeneration exposure beyond metabolic drugs. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Investor attention and commentary: Zacks and other outlets note heavy investor interest and that Lilly has lagged recent market gains despite its headline activity — useful context for short‑term volume/volatility. Eli Lilly (LLY) Ascends But Remains Behind Market
• Negative Sentiment: Competitive pricing pressure: Novo Nordisk launched a higher‑dose Wegovy at a significantly lower cash price than Lilly’s Zepbound/Foundayo positioning, creating margin and market‑share risks in the obesity market. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Analyst downgrade / short‑term sell pressure: reports show at least one analyst downgrade that pushed intraday selling and headlines about the stock dipping after the new approval, reflecting investor sensitivity to competition and side‑effect narratives. Trading Down on Analyst Downgrade Stock Dips Following FDA Approval
• Negative Sentiment: Valuation/forecast adjustments: at least one research note trimmed fair‑value assumptions slightly while leaving a high base case, underscoring debates over how much obesity/diabetes upside is already priced in. Obesity & Diabetes Story Reframes Investment Narrative

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Daiwa Securities Group increased their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Monday. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Rothschild & Co Redburn increased their price target on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Trading Up 2.3%

LLY opened at $952.24 on Thursday. The stock’s fifty day moving average is $987.31 and its two-hundred day moving average is $973.10. The company has a market capitalization of $899.69 billion, a P/E ratio of 41.49, a PEG ratio of 1.09 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the business posted $5.32 EPS. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.